Serge Przedborski, Md - Related publications

Columbia University, New York, NY 
Neurodegeneration, Neurobiology of Disease, Molecular and Cellular Biology of Neurodegeneration, Parkinson's Disease, Motor Neuron Biology and Diseases, Amyotrophic Lateral Sclerosis, Mitochondria Biology and Disease, Mitophagy, Neuroinflammation, Microgl
NOTE: We are testing a new system for identifying relevant work based on semantic analysis that identifies similarities between recently published papers and the current author's publications. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches.
25 most relevant papers in past 60 days:
Year Citation  Score
2022 Zhang J, Sun B, Yang J, Chen Z, Li Z, Zhang N, Li H, Shen L. Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models. Molecular Medicine Reports. 25. PMID 35039876 DOI: 10.3892/mmr.2022.12607   
2022 Soti M, Ranjbar H, Kohlmeier KA, Shabani M. Parkinson's disease related alterations in cannabinoid transmission. Brain Research Bulletin. 178: 82-96. PMID 34808322 DOI: 10.1016/j.brainresbull.2021.11.009   
2022 Li X, Gao D, Paudel YN, Li X, Zheng M, Liu G, Ma Y, Chu L, He F, Jin M. Anti-Parkinson's Disease Activity of Extracts in the MPTP-Induced Zebrafish Model. Acs Chemical Neuroscience. PMID 35044760 DOI: 10.1021/acschemneuro.1c00656   
2022 Anis E, Xie A, Brundin L, Brundin P. Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease. Trends in Endocrinology and Metabolism: Tem. 33: 147-157. PMID 34949514 DOI: 10.1016/j.tem.2021.11.005   
2022 Skelton PD, Tokars V, Parisiadou L. LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights. Cells. 11. PMID 35011731 DOI: 10.3390/cells11010169   
2022 Yin S, Han C, Xia Y, Wan F, Hu J, Kou L, Sun Y, Wu J, Li Y, Zhou Q, Xiong N, Huang J, Wang T. Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A): Could It Be a Promising Biomarker and Therapeutic Target in Parkinson's Disease? Molecular Neurobiology. PMID 34984583 DOI: 10.1007/s12035-021-02670-w   
2022 Ferreira AFF, Singulani MP, Ulrich H, Feng ZP, Sun HS, Britto LR. Inhibition of TRPM2 by AG490 Is Neuroprotective in a Parkinson's Disease Animal Model. Molecular Neurobiology. PMID 35000153 DOI: 10.1007/s12035-022-02723-8   
2022 Luo H, Peng C, Xu X, Peng Y, Shi F, Li Q, Dong J, Chen M. The Protective Effects of Mogroside V Against Neuronal Damages by Attenuating Mitochondrial Dysfunction via Upregulating Sirtuin3. Molecular Neurobiology. PMID 35040040 DOI: 10.1007/s12035-021-02689-z   
2022 Buck SA, Erickson-Oberg MQ, Bhatte SH, McKellar CD, Ramanathan VP, Rubin SA, Freyberg Z. Roles of VGLUT2 and Dopamine/Glutamate Co-Transmission in Selective Vulnerability to Dopamine Neurodegeneration. Acs Chemical Neuroscience. PMID 34994539 DOI: 10.1021/acschemneuro.1c00741   
2022 Xu E, Boddu R, Abdelmotilib HA, Sokratian A, Kelly K, Liu Z, Bryant N, Chandra S, Carlisle SM, Lefkowitz EJ, Harms AS, Benveniste EN, Yacoubian TA, Volpicelli-Daley LA, Standaert DG, et al. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain. Molecular Neurodegeneration. 17: 7. PMID 35012605 DOI: 10.1186/s13024-021-00509-5   
2022 Wu G, Jiang Z, Pu Y, Chen S, Wang T, Wang Y, Xu X, Wang S, Jin M, Yao Y, Liu Y, Ke S, Liu S. Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson's disease patients. Bmc Neurology. 22: 13. PMID 34996385 DOI: 10.1186/s12883-021-02544-7   
2022 Chen SJ, Chen CC, Liao HY, Lin YT, Wu YW, Liou JM, Wu MS, Kuo CH, Lin CH. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients. Neurology. PMID 34996879 DOI: 10.1212/WNL.0000000000013225   
2022 Youn J, Oyama G, Hattori N, Shimo Y, Kuusimäki T, Kaasinen V, Antonini A, Kim D, Lee JI, Cho KR, Cho JW. Subthalamic deep brain stimulation in Parkinson's disease with SNCA mutations: Based on the follow-up to 10 years. Brain and Behavior. e2503. PMID 35040589 DOI: 10.1002/brb3.2503   
2022 Peng H, Li Y, Ji W, Zhao R, Lu Z, Shen J, Wu Y, Wang J, Hao Q, Wang J, Wang W, Yang J, Zhang X. Intranasal Administration of Self-Oriented Nanocarriers Based on Therapeutic Exosomes for Synergistic Treatment of Parkinson's Disease. Acs Nano. PMID 34985280 DOI: 10.1021/acsnano.1c08473   
2022 Wu J, Zhou C, Guo T, Guan X, Gao T, Bai X, Wu H, Chen J, Wen J, Liu X, Gu L, Song Z, Xuan M, Gu Q, Huang P, et al. Cholinergic relevant functional reactivity is associated with dopamine responsiveness of tremor in Parkinson's disease. Brain Imaging and Behavior. PMID 34973120 DOI: 10.1007/s11682-021-00610-9   
2022 Rizzone MG, Mancini F, Artusi CA, Balestrino R, Bonvegna S, Fabbri M, Imbalzano G, Montanaro E, Romagnolo A, Zibetti M, Lopiano L. Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. PMID 34982297 DOI: 10.1007/s10072-021-05730-0   
2022 Conway JA, Kramer ER. Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson's disease? A discussion of data from the culture dish to the clinic. Neural Regeneration Research. 17: 1462-1467. PMID 34916419 DOI: 10.4103/1673-5374.327330   
2022 Hansen CA, Miller DR, Annarumma S, Rusch CT, Ramirez-Zamora A, Khoshbouei H. Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment. Journal of Neurology. PMID 35039902 DOI: 10.1007/s00415-022-10963-w   
2022 Sharma K, Fallon SJ, Davis T, Ankrett S, Munro G, Christopher G, Coulthard E. Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson's disease according to task demands. Psychopharmacology. PMID 35006304 DOI: 10.1007/s00213-021-06054-9   
2022 Ashraf-Uz-Zaman M, Ji G, Tidwell D, Yin L, Thakolwiboon S, Pan J, Junell R, Griffin Z, Shahi S, Barthels D, Sajib MS, Trippier PC, Mikelis CM, Das H, Avila M, et al. Evaluation of Urea-Based Inhibitors of the Dopamine Transporter Using the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis. Acs Chemical Neuroscience. PMID 34978174 DOI: 10.1021/acschemneuro.1c00647   
2022 Mendonça IP, Paiva IHR, Duarte-Silva EP, Melo MG, Silva RSD, Oliveira WH, Costa BLDSAD, Peixoto CA. Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity. International Immunopharmacology. 102: 108415. PMID 34890997 DOI: 10.1016/j.intimp.2021.108415   
2022 Lisek M, Boczek T, Stragierowicz J, Wawrzyniak J, Guo F, Klimczak M, Kilanowicz A, Zylinska L. Hexachloronaphthalene (HxCN) impairs the dopamine pathway in an in vitro model of PC12 cells. Chemosphere. 287: 132284. PMID 34563782 DOI: 10.1016/j.chemosphere.2021.132284   
2022 Gouel F, Timmerman K, Gosset P, Raoul C, Dutheil M, Jonneaux A, Garçon G, Moreau C, Danel-Brunaud V, Duce J, Burnouf T, Devedjian JC, Devos D. Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis. Biomaterials. 280: 121311. PMID 34952382 DOI: 10.1016/j.biomaterials.2021.121311   
2022 Weissbach A, Steinmeier A, Pauly M, Al-Shorafat DM, Saranza G, Lang A, Brüggemann N, Tadic V, Klein C, Münchau A, Bäumer T, Brown MJN. Longitudinal evaluations of somatosensory-motor inhibition in Dopa-responsive dystonia. Parkinsonism & Related Disorders. 95: 40-46. PMID 34999542 DOI: 10.1016/j.parkreldis.2021.12.016   
2022 Tian Q, Tang HL, Tang YY, Zhang P, Kang X, Zou W, Tang XQ. Hydrogen Sulfide Attenuates the Cognitive Dysfunction in Parkinson's Disease Rats via Promoting Hippocampal Microglia M2 Polarization by Enhancement of Hippocampal Warburg Effect. Oxidative Medicine and Cellular Longevity. 2022: 2792348. PMID 35028004 DOI: 10.1155/2022/2792348